This company listing is no longer active
DSM-Firmenich Past Earnings Performance
Past criteria checks 1/6
DSM-Firmenich's earnings have been declining at an average annual rate of -20.7%, while the Chemicals industry saw earnings growing at 10.1% annually. Revenues have been declining at an average rate of 0.8% per year. DSM-Firmenich's return on equity is 4.4%, and it has net margins of 5.4%.
Key information
-20.7%
Earnings growth rate
-20.2%
EPS growth rate
Chemicals Industry Growth | 1.6% |
Revenue growth rate | -0.8% |
Return on equity | 4.4% |
Net Margin | 5.4% |
Next Earnings Update | 02 Aug 2023 |
Recent past performance updates
Recent updates
Analyst Forecasts For Koninklijke DSM N.V. (AMS:DSM) Are Surging Higher
May 04Koninklijke DSM (AMS:DSM) Is Reinvesting At Lower Rates Of Return
Mar 27Is Koninklijke DSM (AMS:DSM) A Risky Investment?
Mar 09Here's Why We Think Koninklijke DSM (AMS:DSM) Is Well Worth Watching
Dec 06Is Koninklijke DSM (AMS:DSM) Using Too Much Debt?
Nov 18Estimating The Fair Value Of Koninklijke DSM N.V. (AMS:DSM)
Oct 31Why Koninklijke DSM N.V. (AMS:DSM) Could Be Worth Watching
Sep 19Is Now The Time To Put Koninklijke DSM (AMS:DSM) On Your Watchlist?
Aug 23Is Koninklijke DSM (AMS:DSM) Using Too Much Debt?
Aug 08Calculating The Intrinsic Value Of Koninklijke DSM N.V. (AMS:DSM)
Jul 23Koninklijke DSM (AMS:DSM) Is Increasing Its Dividend To €1.70
Apr 30Koninklijke DSM (AMS:DSM) Is Increasing Its Dividend To €1.70
Apr 16Koninklijke DSM's (AMS:DSM) Upcoming Dividend Will Be Larger Than Last Year's
Apr 02Koninklijke DSM's (AMS:DSM) Dividend Will Be Increased To €1.70
Mar 19Koninklijke DSM (AMS:DSM) Seems To Use Debt Rather Sparingly
Feb 19Are Koninklijke DSM N.V. (AMS:DSM) Investors Paying Above The Intrinsic Value?
Nov 23We Think Koninklijke DSM (AMS:DSM) Can Stay On Top Of Its Debt
Oct 01Does This Valuation Of Koninklijke DSM N.V. (AMS:DSM) Imply Investors Are Overpaying?
Aug 24Koninklijke DSM (AMS:DSM) Has A Pretty Healthy Balance Sheet
Jun 29Koninklijke DSM N.V.'s (AMS:DSM) Intrinsic Value Is Potentially 17% Below Its Share Price
May 24Is Koninklijke DSM (AMS:DSM) A Risky Investment?
Mar 29Should Koninklijke DSM N.V. (AMS:DSM) Be Part Of Your Dividend Portfolio?
Mar 15Are Koninklijke DSM N.V.'s (AMS:DSM) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Mar 01Koninklijke DSM (AMS:DSM) Has Gifted Shareholders With A Fantastic 276% Total Return On Their Investment
Feb 16Need To Know: Koninklijke DSM N.V. (AMS:DSM) Insiders Have Been Selling Shares
Feb 04Revenue & Expenses Breakdown
How DSM-Firmenich makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 22 | 8,390 | 454 | 1,772 | 295 |
30 Sep 22 | 9,582 | 837 | 895 | 162 |
30 Jun 22 | 9,802 | 1,082 | 1,789 | 323 |
31 Mar 22 | 9,503 | 1,081 | 1,789 | 323 |
31 Dec 21 | 7,269 | 820 | 1,649 | 274 |
30 Sep 21 | 7,955 | 660 | 2,517 | 560 |
30 Jun 21 | 7,558 | 493 | 1,622 | 398 |
31 Mar 21 | 7,572 | 423 | 1,622 | 398 |
31 Dec 20 | 8,106 | 448 | 1,622 | 398 |
30 Sep 20 | 7,960 | 510 | 1,639 | 295 |
30 Jun 20 | 8,034 | 557 | 1,639 | 295 |
31 Mar 20 | 9,011 | 722 | 1,795 | 349 |
31 Dec 19 | 7,998 | 675 | 1,639 | 295 |
30 Sep 19 | 8,272 | 820 | 1,839 | 348 |
30 Jun 19 | 8,502 | 794 | 1,839 | 348 |
31 Mar 19 | 9,124 | 934 | 1,839 | 348 |
31 Dec 18 | 9,267 | 1,069 | 1,839 | 348 |
30 Sep 18 | 9,235 | 984 | 1,753 | 334 |
30 Jun 18 | 9,106 | 2,082 | 1,753 | 334 |
31 Mar 18 | 8,908 | 1,942 | 1,753 | 334 |
31 Dec 17 | 8,632 | 1,761 | 1,753 | 334 |
30 Sep 17 | 8,471 | 1,676 | 1,694 | 309 |
30 Jun 17 | 8,333 | 738 | 1,694 | 309 |
31 Mar 17 | 8,166 | 711 | 1,694 | 309 |
31 Dec 16 | 7,920 | 645 | 1,694 | 309 |
30 Sep 16 | 7,831 | 588 | 1,605 | 332 |
30 Jun 16 | 7,778 | 274 | 1,605 | 332 |
31 Mar 16 | 7,749 | 214 | 1,605 | 332 |
31 Dec 15 | 7,722 | 174 | 1,605 | 332 |
30 Sep 15 | 7,607 | 66 | 1,382 | 304 |
30 Jun 15 | 7,456 | 114 | 1,382 | 304 |
31 Mar 15 | 7,245 | 115 | 1,382 | 304 |
31 Dec 14 | 7,051 | 123 | 1,382 | 304 |
30 Sep 14 | 7,415 | 112 | 1,430 | 340 |
30 Jun 14 | 7,834 | 138 | 1,430 | 340 |
31 Mar 14 | 8,362 | 182 | 1,430 | 340 |
31 Dec 13 | 8,858 | 252 | 1,430 | 340 |
30 Sep 13 | 8,409 | 363 | 1,396 | 372 |
30 Jun 13 | 8,500 | 335 | 1,396 | 372 |
31 Mar 13 | 8,486 | 257 | 1,396 | 372 |
31 Dec 12 | 8,588 | 280 | 1,396 | 372 |
30 Sep 12 | 9,089 | 453 | 1,356 | 378 |
30 Jun 12 | 9,107 | 543 | 1,356 | 378 |
Quality Earnings: DSM has high quality earnings.
Growing Profit Margin: DSM's current net profit margins (5.4%) are lower than last year (11.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DSM's earnings have declined by 20.7% per year over the past 5 years.
Accelerating Growth: DSM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: DSM had negative earnings growth (-44.6%) over the past year, making it difficult to compare to the Chemicals industry average (-19.7%).
Return on Equity
High ROE: DSM's Return on Equity (4.4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2023/05/31 16:43 |
End of Day Share Price | 2023/05/30 00:00 |
Earnings | 2022/12/31 |
Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
DSM-Firmenich AG is covered by 61 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Mutlu Gundogan | ABN AMRO Bank N.V. |
Martin Schnee | AlphaValue |
Volker Bosse | Baader Helvea Equity Research |